

Press Releases

All Years

[Advanced Search](#)

JAN 22, 2013

[Perrigo Launches Store Brand Version Of Nicorette® Mini Nicotine Lozenges](#)

JAN 18, 2013

[Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013](#)

JAN 15, 2013

[Perrigo Announces Commercial Launch Of betamethasone valerate foam 0.12%](#)

JAN 7, 2013

[Perrigo Announces Launch of Authorized Generic Version of Acetadote® \(acetylcysteine\) Injection](#)

JAN 7, 2013

[Perrigo Gains FDA Clearance To Manufacture Three Codex-Compliant Infant Formulas To Meet Growing Demand From International Markets](#)

JAN 2, 2013

[Perrigo Company To Present At The J.P. Morgan Healthcare Conference](#)

DEC 28, 2012

[Perrigo Company Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately \\$45 Million](#)

-- Solidifies Perrigo's leadership position in topical foam-based generic prescription pharmaceuticals

DEC 4, 2012

[Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx](#)

NOV 28, 2012

[Perrigo Confirms Settlement Of Generic Version Of Ofirmev® \(acetaminophen\) Injection Patent Litigation](#)

NOV 27, 2012

[Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%](#)

NOV 13, 2012

[Perrigo Company To Present At The Credit Suisse Healthcare Conference](#)

NOV 13, 2012

[Perrigo Confirms Settlement Of Generic Version Of Acetadote® \(acetylcysteine\) Injection Patent Litigation](#)

NOV 7, 2012

[Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance](#)

[And Raises Full Year Adjusted ETC Guidance](#)

- Fiscal first quarter adjusted net income increased 16% to a record \$119 million, or \$1.27 per diluted share, inclusive of an \$0.08 tax benefit.

NOV 6, 2012

[Perrigo Company Announces Appointment Of New Board Of Directors Member](#)

NOV 6, 2012

[Perrigo Company Announces Quarterly Dividend](#)

OCT 23, 2012

[Perrigo Company Will Release First Quarter Fiscal Year 2013 Results on November 7, 2012](#)

OCT 16, 2012

[Perrigo Confirms FDA Tentative Approval For OTC Version Of Omeprazole And Sodium Bicarbonate Capsules](#)

OCT 10, 2012

[Perrigo Receives FDA Approval To Market Mini Nicotine Lozenges](#)

OCT 1, 2012

[Perrigo Closes Acquisition Of Sergeant's Pet Care Products](#)

SEP 18, 2012

[Perrigo Company to Present at the UBS Global Life Sciences Conference](#)



SEP 13, 2012

[Perrigo Company To Acquire Assets Of Sergeant's Pet Care Products, Inc., For \\$285 Million](#)

-- Sergeant's Pet Care Products, Inc., a privately-held OTC animal health company, expands Perrigo's portfolio to include a new adjacent product category, companion animal healthcare

SEP 7, 2012

[Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference](#)

SEP 6, 2012

[Perrigo Confirms First To File Patent Challenge For Generic Version Of ProAir® HFA Inhalation Aerosol](#)

AUG 27, 2012

[Perrigo and Tris Pharma Launch Store Brand Version of Delsym®](#)

AUG 16, 2012

[Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations](#)

- Full-year revenue from continuing operations increased \$418 million, or 15%, to a record \$3.2 billion.



AUG 15, 2012

[Perrigo Company Announces Quarterly Dividend](#)

AUG 9, 2012

[Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%](#)

AUG 8, 2012

[Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution](#)

AUG 2, 2012

[Perrigo Company Will Release Fourth Quarter And Fiscal Year 2012 Results On August 16, 2012](#)

JUN 27, 2012

[Perrigo Receives FDA Approval and Commences Launch of Clindamycin Phosphate and Benzoyl Peroxide 1.2% / 5% Gel](#)

JUN 11, 2012

[Perrigo Announces Settlement of Clobetasol Propionate E-Foam 0.05% Patent Litigation](#)

JUN 8, 2012

[Perrigo Company To Present At The William Blair Growth Stock Conference](#)

JUN 6, 2012

[Perrigo Receives FDA Approval for Calcium Acetate Capsules](#)

MAY 30, 2012

[Perrigo Announces FDA Final Approval Of Tris Pharma's Dextromethorphan Polistirex Extended-Release Oral Suspension](#)

MAY 24, 2012

[Perrigo Company To Present At Upcoming Healthcare Conferences](#)

MAY 22, 2012

[Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream](#)

MAY 18, 2012

[Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules](#)

MAY 15, 2012

[Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference](#)

MAY 8, 2012

[Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance](#)

-- Fiscal third quarter revenue from continuing operations increased \$86 million, or 13%, to \$778 million

MAY 3, 2012

[Perrigo Company Announces Quarterly Dividend](#)

APR 24, 2012

[Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012](#)

APR 12, 2012

[Perrigo Announces the Launch of Guaifenesin Extended-Release 600mg Tablets -- to Compare to Mucinex® 600mg](#)

MAR 21, 2012

[Perrigo Announces Australian Approval for Generic Temozolomide](#)

MAR 13, 2012

[Perrigo Company to Present at the Barclays Capital Global Healthcare Conference](#)

MAR 1, 2012

[Perrigo Announces the First Store Brand Launch of the Generic Version of Rogaine® 5% Foam](#)

FEB 28, 2012

[Perrigo Company to Present at the RBC Capital Markets' Healthcare Conference](#)

FEB 14, 2012

[Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12](#)

FEB 8, 2012

[Perrigo Company to Present at the Leerink Swann 2012 Global Healthcare Conference](#)

FEB 7, 2012

[Perrigo Reports Record Quarterly Revenue and Earnings](#)

- Fiscal second quarter revenue from continuing operations increased \$121 million, or 17%, to a record \$838 million

FEB 2, 2012

[Perrigo Company Announces Quarterly Dividend](#)

Show per
page

[«](#) [1](#) ... [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) ... [19](#) [»](#)



<https://investor.perrigo.com/press-releases?l=50&o=550>